Almost 2 years we been living in the shadow/fear of a virus. When we thought we almost conquer it. It transformed like Megaton into another mutation/variant.
During this period,  many seasoned traders felt that their portfolio was infected by Covid & suffered a setback.
While new traders felt that their portfolio is on "vaccinated" journey 🚀🌛. However,  the journey to the moon may ended in explosion for some newbies. When they realised it, they're on 🔥 🔥 🔥  in flames.
Forging ahead, as retail traders, we may never see the far months ahead. Maybe the Mega Storm is lurking not far in the future. But what we can do, is to give our offering 🍗🍗 (investment) to the Market God. Some sacrifice👰‍♂️(losses) will be made in order to please the Market God to lead us to prosperity 💰💰 (uptrend)
Huat Ah 2022 发发发 🚀🚀🌛🌛
$Tesla (TSLA.US)$
$Apple (AAPL.US)$
$SNDL Inc (SNDL.US)$
$AMC Entertainment (AMC.US)$
$Palantir (PLTR.US)$
$Genting Sing (G13.SG)$
$Lucid Group (LCID.US)$
$SIA (C6L.SG)$
$Futu Holdings Ltd (FUTU.US)$
$UP Fintech (TIGR.US)$
$Camber Energy (CEI.US)$
$XPeng (XPEV.US)$
$NIO Inc (NIO.US)$
$Alibaba (BABA.US)$
$Pfizer (PFE.US)$
$Grab Holdings (GRAB.US)$
$BlackBerry (BB.US)$
$Moderna (MRNA.US)$
$Singtel (Z74.SG)$

$Futu Holdings Ltd (FUTU.US)$ Don't sell, don't lose.

$Block (SQ.US)$ Tax preparation company H&R Block Inc on Thursday sued payment company Block Inc, previously called Square Inc, saying the new name infringed its trademarks.
$Ford Motor (F.US)$ $NVIDIA (NVDA.US)$ New car sales in the US are expected to rise next year, driven by pent up demand as automakers were forced to cut production in 2020 and 2021 amid the semiconductor shortage. Edmunds expects 15.2 million more cars will be sold in 2022, a 1.2% increase despite higher prices.

$Pfizer (PFE.US)$ The Pfizer jab is "the hardest to deliver given ultra-cold chain and special syringe requirements", Gavi says in its internal document. It is also "the hardest to plan for as these (donated vaccines) often come with earmarking and little notice or in a staggered manner and in small volumes and with short shelf lives". Wealthy countries donating COVID-19 vaccines with a relatively short shelf life has been a "major problem" for COVAX, a WHO official said last week, as many doses were wasted.

Shares of Biofrontera Inc. (BFRI) $Biofrontera (BFRI.US)$ are rising more than 13% in the morning trade on Monday.
Today, the company said that the first patient has been enrolled in the Phase 2 study to evaluate the safety and efficacy of the company's FDA approved product, Ameluz in combination with BF-RhodoLED for the treatment of moderate-to-severe acne with photodynamic therapy.
"This study is an important component of Biofrontera group's clinical development strategy that aims to expand the FDA-label of our licensed product Ameluz. The inclusion of additional indications aims at unlocking its full therapeutic and market potential in the US," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc.
BFRI, currently at $6.08, has traded in the range of $2.25- $10.40 in the last one year.
Content is taken from Nasdaq.

$XPeng (XPEV.US)$ 👍👍👍

$Vir Biotechnology (VIR.US)$
entered at 39.99 few days ago and now it's going uppppp